These results suggest that T28zT2 T cells were more effective than DNTR T cells at in vivo tumor killing, possibly as T28zT2 T cells rewired TGF-β signaling further into CAR signaling, promoting their effector function, compared with DNTR T cells. The gene discussed is TGFB1; the disease is neoplasm.